Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
23 Results for "
adrenoleukodystrophy
" in MedChemExpress (MCE) Product Catalog:
Products (23)
23 Results for "adrenoleukodystrophy" in MCE Product Catalog:
2
2 Cited Publications
Synonyms: Tetracosanoic acid
Category:
Target:
2
2 Cited Publications
Target:
Research Areas:
ELOVL1-IN-3 (Compound 22) is a potent and orally active inhibitor of elongation of very long chain fatty acid 1 (ELOVL1) enzyme. ELOVL1-IN-3 serves as a useful tool for researching adrenoleukodystrophy (ALD) [1].
1
Category:
Cardiovascular Disease Ketones, Aldehydes, Acids Disease markers Endocrine diseases Nervous System Disorder Endogenous metabolite Disease Research Fields
Target:
1
1 Cited Publications
Target:
Research Areas:
ELOVL1-IN-1 is an ELOVL1 inhibitor extracted from patent WO2018107056A1, compound 87. ELOVL1-IN-1 can reduce very long chain fatty acid levels. ELOVL1-IN-1 can be used for the research of adrenoleukodystrophy (ALD) .
Cat. No.: HY-160004
CAS No.: 1523493-53-9
Target:
PXL770 is an orally active, direct allosteric AMP-activated protein kinase (AMPK) activator. PXL770 decreases C26:0 levels, improves mitochondrial respiration, reduces expression of proinflammatory genes and induces expression of compensatory transporters (ABCD2/3) in ALD fibroblasts/lymphocytes. PXL770 normalizes plasma VLCFA levels, significantly reduces elevated VLCFA levels in brain and spinal cord in Abcd1 KO mice. PXL770 improves glycemia, dyslipidemia, and insulin resistance in ob/ob and high-fat diet (HFD)-fed mice. PXL770 can be used for the study of X-linked adrenoleukodystrophy (ALD), autosomal dominant polycystic kidney disease and nonalcoholic steatohepatitis (NASH) .
Target:
Research Areas:
ELOVL1-IN-2 is an elongation of very long chain fatty acid 1 (ELOVL1) enzyme inhibitor, ELOVL1-IN-2 shows weak ELOVL1 inhibition (IC50=21 μM) and moderate potency in a primary cellular assay (HEK293 C26 IC50=6.7 μM) .
Target:
Research Areas:
VK-0214 is an agonist of the thyroid β receptor (TRβ). By activating the expression of ABCD2, it can reduce the accumulation of very long-chain fatty acids (VLCFAs) and further alleviate glioblastoma multiforme. VK-0214 has the effect of regulating fatty acid metabolism and can be used in the research of X-linked adrenoleukodystrophy (X-ALD) .
Category:
other families Ketones, Aldehydes, Acids Metabolic Disease Plants Endogenous metabolite Disease Research Fields
Target:
Synonyms: Tetracosanoic acid-d47
Synonyms: Tetracosanoic acid-d4-2
Synonyms: Tetracosanoic acid-d3
Cat. No.: HY-124422R
CAS No.: 506-38-7
Cat. No.: HY-113301R
CAS No.: 506-46-7
Cat. No.: HY-113301S
CAS No.: 1208837-79-9
Cat. No.: HY-113301S2
CAS No.: 2692624-17-0
Cat. No.: HY-W331017
CAS No.: 1213783-80-2
Synonyms: 26:0 Lyso PC
Cat. No.: HY-121883R
CAS No.: 557-59-5
Synonyms: Tetracosanoic acid (Standard)
Category:
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
